TUMOR, SOLID

This is a first-in-human study testing a new type of personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D). The therapy involves collecting a patient's own immune cells (T cells), genetically engineering them in a lab to …

This study is testing a new experimental drug called CNSI-Fe, which is an iron-loaded nanoparticle suspension injected directly into tumors. The goal is to see if it is safe and can help control cancer in people with advanced solid tumors that have stopped responding to standard …

This early-stage study aims to find a safe dose of the drug nab-sirolimus for adults with advanced solid tumors who also have moderate liver problems. It will compare how the drug is processed in the body between these patients and those with normal liver function. The main goal …

This is a first-in-human study to find a safe and effective dose of a new drug called ONM-501. The drug is injected directly into tumors and is being tested alone and in combination with an approved immunotherapy drug (cemiplimab) in adults with advanced cancers that have stopped…

This program provides access to an experimental drug called AVM0703 for patients with various solid tumors and blood cancers. It is for people who may not have other treatment options. The drug aims to help the body's immune system fight cancer, and early reports show mostly mild…

This early-stage trial is testing the safety and best dose of a new two-drug combination (ulixertinib and palbociclib) for people with advanced solid tumors that have stopped responding to standard treatments. It will enroll up to 45 adults, with a specific focus on metastatic pa…

This is a very early-stage study testing a new type of personalized treatment for people with advanced solid tumors. Doctors will collect a patient's own immune cells, genetically modify them to target a specific cancer mutation (KRAS G12V or G12D), and infuse them back into the …

This early-stage study is testing a new cancer drug called INV-1120, both by itself and combined with an existing immunotherapy (pembrolizumab), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe dose levels a…

This early-stage trial is testing a new personalized cell therapy called LEU011 for people with advanced solid tumors that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how well patients tolerate the treatment. Research…

This is the first study in people to test a new drug called NTX-1088, an antibody designed to target a protein found on many cancer cells. The main goals are to find safe doses and see how the body processes the drug, both by itself and when combined with an existing immunotherap…

This study is testing a special fluorescent dye called indocyanine green (TumorGlow™) that is given before surgery. The dye makes cancer cells glow under a special camera, helping surgeons see and remove more of the tumor. The research aims to find the safest and most effective d…

This early-stage study is testing a personalized mRNA vaccine designed to teach the immune system to attack a patient's specific cancer. It is for adults with solid tumors who have had surgery but are at high risk of the cancer returning. The main goal is to find the safest dose …

This study aims to identify blood markers that can predict whether cancer patients will respond to FDA-approved immunotherapy treatments. Researchers will follow 1,500 patients receiving treatments like pembrolizumab or nivolumab, tracking their response over six months. The goal…